Stock 688319 CHENGDU OLYMVAX BIOPHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Chengdu Olymvax Biopharmaceuticals Inc.

Equities

688319

CNE1000051H8

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-06-06 pm EDT 		5-day change 1st Jan Change
10 CNY +1.11% Intraday chart for Chengdu Olymvax Biopharmaceuticals Inc. +3.20% -36.71%
May. 16 Olymvax Biopharma's Flu Vaccine Gets China Nod for Clinical Trials MT
Apr. 25 Chengdu Olymvax Biopharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • The group's high margin levels account for strong profits.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • Analyst opinion has improved significantly over the past four months.

Weaknesses

  • With an expected P/E ratio at 52.63 and 30.77 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The company is not the most generous with respect to shareholders' compensation.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
CHENGDU OLYMVAX BIOPHARMACEUTICALS INC. Stock Chengdu Olymvax Biopharmaceuticals Inc.
-36.71% 560M -
CSL LIMITED Stock CSL Limited
+0.82% 91.94B
A-
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
-1.32% 38.74B
A-
BIOGEN INC. Stock Biogen Inc.
-12.88% 32.82B
B-
UCB Stock UCB
+64.77% 26.66B
A
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-16.31% 15.32B
C
INCYTE CORPORATION Stock Incyte Corporation
-5.78% 13.3B
B-
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-11.38% 11.65B
D+
ALTEOGEN INC. Stock ALTEOGEN Inc.
+173.10% 10.37B
D
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-49.84% 10.12B
B
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
-
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
  1. Stock Market
  2. Equities
  3. 688319 Stock
  4. Ratings Chengdu Olymvax Biopharmaceuticals Inc.